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Perspectives
In recent years, the incidence of car-
diovascular diseases, diabetes, cancers 
and chronic respiratory diseases has 
increased in epidemic proportions in 
many low-resource countries, includ-
ing Bangladesh.1 Noncommunicable 
diseases accounted for an estimated 38 
of 56 million deaths worldwide in 2012. 
Yet most of the deaths (74%, 28 million) 
occurred in low- and middle-income 
countries, where access to essential 
medicines to prevent and treat these dis-
eases remains low.2,3 The Global Burden 
of Disease study projected that noncom-
municable diseases will be the leading 
global cause of disability by 2030.4
Lack of access to essential medi-
cines for noncommunicable diseases is 
a major challenge for the health systems 
in many low-resource countries, poten-
tially contributing to increased mortality 
and morbidity in these countries.5 The 
World Health Organization (WHO) 
has recommended that every country 
should have a national drug policy that 
ensures access, quality and rational use 
of medicines as an integral part of its 
broader strategic health-care policy.6 It 
has also recommended that noncom-
municable diseases be incorporated into 
the strategic plans of national drug poli-
cies.7 The WHO Model list of essential 
medicines contains 95 basic medicines 
for most noncommunicable diseases, 
including 16 new medicines for cancer 
that were added in May 2015.8 Despite 
the wide adoption of national drug 
policies in low- and middle-income 
countries, the majority of these do not 
include essential medicines for noncom-
municable diseases.
Bangladesh is one of the pioneer 
countries to develop a national drug 
policy, launching its first in 1982. Based 
on the WHO essential medicines con-
cept, the national drug policy identi-
fied 150 essential drugs for controlled 
pricing. The policy was instrumental in 
improving the supply and accessibility 
of quality essential drugs at an afford-
able price.9 However, during the 1980s 
and 1990s in Bangladesh the quality 
assurance of medicines started to be 
neglected, the price of local medicines 
increased and there was a shift in pro-
duction from essential medicines to 
more profitable unregulated medicines 
by the major pharmaceutical industries. 
Despite being one of the world’s poorest 
countries, Bangladesh has made great 
progress over the last few decades in 
reducing maternal and child mortality, 
decreasing the burden of communicable 
diseases and improving life expectancy.10
In 2011, the Government of Ban-
gladesh adopted a new national health 
policy, incorporating a strategic plan 
for the surveillance and prevention of 
noncommunicable diseases, along with 
a plan for the provision of essential 
drugs for these diseases.10 However, 
these policy documents did not mention 
specific medicines for noncommuni-
cable diseases or requirements for their 
availability, price, quality assurance or 
rational use. 
Many issues prevented the optimal 
implementation of the essential drugs 
and noncommunicable diseases’ policies 
in Bangladesh: lack of specific financial 
resources; lack of leadership and ac-
countability; insufficient planning and 
forecasting; inefficient procurement; 
coordination and monitoring; and other 
competing priorities. However, several 
countries have undertaken initiatives to 
promote access to medicines for these 
diseases. For example, the Brazilian gov-
ernment, through its popular pharmacy 
programme, partnered with private 
pharmacies to market subsidized medi-
cines for noncommunicable diseases, a 
scheme that can be replicated in other 
countries.11
Most noncommunicable diseases 
can be treated or managed with a small 
range of low-cost generic medicines 
such as anti-hypertensives, statins and 
other cardiovascular drugs, analgesics, 
anti-asthmatics and some common 
anti-cancer drugs.2 However, many of 
the essential medicines for diabetes in 
Bangladesh are too expensive for the 
general population or are not avail-
able in government facilities.12 A study 
in 2016 found that for patients with 
diabetes the cost of drugs accounted for 
the largest share of their total health-
care expenditure.13 From its inception 
the Bangladesh national drug policy 
failed to include some of the essential 
medications from the WHO essential 
list for cancer, diabetes, cardiovascular 
diseases, respiratory diseases and mental 
illnesses. The 209 medicines in the Ban-
gladesh essential medicines list for 2008 
included only 30 drugs for noncommu-
nicable diseases (Table 1). Furthermore, 
many medicines for noncommunicable 
diseases are not widely prescribed or 
available, as pharmaceutical companies 
and physicians might prefer to promote 
more expensive, profit-yielding drugs. 
Counterfeit versions of costly drugs 
may also be available in the market 
and might be promoted by local phar-
macies for higher profits. Moreover, 
several pharmaceutical companies in 
Bangladesh lack heating, ventilation, 
air-conditioning systems and warehouse 
facilities that conform to internationally 
mandated standards.15 In addition, the 
Bangladesh drug regulatory authority 
has constrained resources to monitor 
the quality of medicines produced and 
imported into the country.
In 2012, WHO Member States 
agreed on a set of indicators for drugs 
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and technologies for noncommunicable 
diseases. These included assessing the 
availability of 80% of generic essential 
medicines for noncommunicable dis-
eases in public and private facilities, 
and a voluntary target that 50% of the 
population at risk of heart attacks and 
stroke receive appropriate drug therapy 
and counselling.2 The Noncommuni-
cable Diseases Alliance recommends the 
critical evaluation of guidelines, prices, 
availability, accessibility, financing and 
quality of medicines and services for 
noncommunicable diseases; that pricing 
policies be reviewed ; and the capacity 
of the national drug regulatory authority 
be strengthened to ensure the quality, 
safety and efficacy of essential medicines 
and technologies in the country.5 These 
recommendations place additional 
pressure on low- and middle-income 
countries to improve access to, and 
availability of, medicines for noncom-
municable diseases. However, care for 
such diseases is still inadequate within 
the primary-care setting in Bangladesh 
and other low-resource countries, pri-
marily due to a shortage of equipment, 
medicines and trained staff, and a focus 
on maternal and child health. This cre-
ates a considerable challenge to incor-
porate all the WHO essential medicines 
for noncommunicable diseases into the 
national essential medicines list.
In most low-resource countries, 
multiple barriers exist to reforming the 
national drug policy, which are often 
complex and go beyond simple financial 
constraints. These include political in-
stability, bureaucratic inertia, resistance 
from entrenched interest groups eager 
to protect the existing policy, govern-
ment financial constraints, and policy 
issues that often transcend borders.6 In 
many cases, the lack of national clinical 
guidelines for noncommunicable dis-
eases hinders the selection of essential 
medicines for these diseases. Generally, 
the inclusion of a drug in the national 
drug policy mandates its provision in 
government-funded care settings. This 
is made more complex by the high cost 
of medicines for cancer, and some patent 
drugs with little or no clinical benefits 
over existing standard medicines, which 
resource-poor governments cannot 
afford to provide. In many low- and 
middle-income countries decisions on 
the cost‒effectiveness of drugs therefore 
have to be made, which in themselves 
pose considerable technical and re-
source challenges for already stretched 
departments of health. Other potential 
barriers to national drug policy reform 
may include weak supply systems from 
storage facilities to clinics; weak regu-
lations and quality assurance; limited 
capacity of national drug regulatory au-
thorities; irrational drug prescribing and 
dispensing; and limited market competi-
tion for critical essential medicines. In 
addition, there may be opposition to a 
national drug policy from clinicians, due 
to fear of loss of clinical freedom, and 
from pharmacies and pharmaceutical 
companies, due to competing interests.
Evidence from several countries 
suggests that a comprehensive approach 
is required to overcome these barriers. 
In Sweden, the drug and therapeutics 
committee in Stockholm created a re-
gional list of 200 essential drug recom-
mendations for use in ambulatory care, 
and demonstrated 87% adherence to 
the recommendations by physicians.16 
Identifying and implementing strategies 
to improve the use of essential medi-
cines is needed using strong legislative 
frameworks, and political will, com-
mitment and support for national drug 
policies. The national drug policy needs 
to be embedded in the national health 
policies and health systems. Along with 
strengthening the national drug regula-
tory authorities, other essential elements 
for a sustainable national drug policy 
include greater allocation of financial 
resources, and identifying alternative 
mechanisms such as pre-payment, tax, 
pricing policies, promoting generic 
medicines and negotiations with global 
trade agreements (e.g. measures com-
pliant with the Trade-Related Aspects 
of Intellectual Property Rights). Using 
central procurement and distribution 
can increase the availability of high-
quality essential medicines. Other mea-
sures include promoting rational use of 
medicines, preventing inappropriate 
drug promotion, capacity-building 
for human resources, promoting drug 
information centres, publishing drug 
bulletins, providing consumer informa-
tion and education, and strengthening 
multisectoral collaboration.17
Noncommunicable diseases im-
pose a heavy financial burden on 
affected individuals, families and the 
economy in countries such as Ban-
gladesh. The responsiveness of the 
Bangladesh national drug policy to 
the country’s rapid epidemiological 
transition and increased burden of 
noncommunicable diseases remains 
weak. Ensuring accessibility, rational 
prescribing and quality of essential 
medicines for these diseases needs to be 
prioritized, alongside strategies such as 
lifestyle changes and tobacco and other 
taxes. In short, there is an urgent need 
Table 1. Number of medicines for noncommunicable diseases in the Bangladesh and 
World Health Organization lists of essential drugs
Category WHO list Bangladesh list
No. of 
medicines
No. of 
medicines
Names
Noncommunicable 
diseases
Cancers 40 7 Cisplatin, cyclophosphamide, 
methotrexate, procarbazine, 
tamoxifen, vinblastine, vincristine
Diabetes 5 4 Glibenclamide, gliclazide, insulin, 
metformin
Cardiovascular 
diseases
28 13 Atenolol, digoxin, enalapril, 
furosemide, glyceryl trinitrate, 
isosorbide dinitrate, nifedipine, 
methyldopa, procainamide, 
propranolol, spironolactone, 
verapamil, warfarin
Mental health 
disorders
17 5 Amitryptiline, fluorouracil, 
fluphenazine, haloperidol, lithium 
carbonate
Respiratory diseases 5 1 Salbutamol
All diseases 410 209 N/A
N/A: not applicable; WHO: World Health Organization.
Sources: WHO Model list of essential medicines, 20158 and Bangladesh List of essential drugs, 2008.14
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to reform the national drug policy to 
incorporate noncommunicable diseases 
within its mandate, so that treatment 
and essential drugs for these diseases 
could be made available and accessible 
to all, especially poor and disadvan-
taged people. Potential approaches that 
Bangladesh and other low-resource 
countries could apply in the short, me-
dium and long term include: (i) estab-
lishing national treatment guidelines 
and protocols for noncommunicable 
diseases; (ii) increasing the availabil-
ity and affordability of medicines for 
noncommunicable diseases through 
central procurement and distribution; 
(iii) increasing government subsidies 
for noncommunicable diseases’ medi-
cines through tax revenue, for example 
by imposing taxes on sugary drinks, or 
increasing tobacco and alcohol taxes; 
and (iv) developing sustainable mecha-
nisms for promoting accessibility to 
noncommunicable diseases’ medicines 
for all patients, for example via sale of 
government-subsidized medicines in 
community pharmacies.
Such a reform of the national drug 
policy would not only strengthen the 
health system and help achieve univer-
sal health coverage, but also reduce the 
mortality and morbidity attributable 
to noncommunicable diseases in these 
countries. ■
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